- Medtronic plc (NYSE:MDT) announced early data for its self-expanding Intrepid transcatheter mitral valve replacement (TMVR) system for mitral valve regurgitation (MR) utilizing the transfemoral access route.
- Data from the first 15 patients enrolled in an Early Feasibility Study of the Intrepid Transfemoral System showed 100% survival and no stroke, a median procedure time of 46 minutes, and none/trace MR in all implanted patients at 30 days.
- The data were published simultaneously in the American College of Cardiology (JACC): Cardiovascular Intervention.
- Mitral regurgitation (MR) occurs when blood flows backward through the mitral valve and into the atrium when the left ventricle contracts.
- The Intrepid valve has been used to treat more than 350 patients as part of global clinical trials.
- The Intrepid TMVR system is only available for investigational use, and it is not approved outside of clinical studies.
- Related: Medtronic Touts 5-Year Data Of Self-Expanding TAVR Platform.
- Price Action: MDT shares closed at $122.98 on Friday.
How Much Wealth Did Elon Musk Lose In This Week’s Tesla Stock Rout?
The U.S. stock market is in doldrums, with the S&P 500 Index officially dropping into bear market territory on Friday. The brutal drubbing hasn't spared the world's richest, wiping away billions of their net worth.
